Form **8937**
(December 2017)
Department of the Treasury
Internal Revenue Service

Report of Organizational Actions Affecting Basis of Securities

► See separate instructions.

OMB No. 1545-0123

Part I Reporting Issuer

1 Issuer's name VYNE THERAPEUTICS INC. (NOW YARROW BIOSCIENCE, INC .)			2 Issuer's employer identification number (EIN) 45-3757789
3 Name of contact for additional information TYLER ZERONDA	4 Telephone No. of contact (203) 433-7577		5 Email address of contact INFO@YARROWBIOSCIENCE.COM
6 Number and street (or P.O. box if mail is not delivered to street address) of contact 470 JAMES STREET, SUITE 007			7 City, town, or post office, state, and ZIP code of contact NEW HAVEN, CT 06513
8 Date of action JULY 23, 2026	9 Classification and description COMMON STOCK DISTRIBUTION		
10 CUSIP number SEE LINE 19 BELOW	11 Serial number(s)	12 Ticker symbol SEE ATTACHMENT	13 Account number(s)

Part II Organizational Action Attach additional statements if needed. See back of form for additional questions.

14 Describe the organizational action and, if applicable, the date of the action or the date against which shareholders' ownership is measured for the action ► SEE ATTACHMENT

15 Describe the quantitative effect of the organizational action on the basis of the security in the hands of a U.S. taxpayer as an adjustment per share or as a percentage of old basis ► SEE ATTACHMENT

16 Describe the calculation of the change in basis and the data that supports the calculation, such as the market values of securities and the valuation dates ► SEE ATTACHMENT

Part II **Organizational Action** *(continued)*

17 List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ▶ SEE ATTACHMENT

18 Can any resulting loss be recognized? ▶ SEE ATTACHMENT

19 Provide any other information necessary to implement the adjustment, such as the reportable tax year ▶ SEE ATTACHMENT

Sign Here

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

Signature ▶ Date ▶ 09/03/26

Print your name ▶ TYLER ZERONDA Title ▶ CFO

Paid Preparer Use Only				
Print/Type preparer's name: MATTHEW SCALITI	Preparer's signature	Date: 09/03/26	Check ☐ if self-employed	PTIN: P00960286
Firm's name ▶ RSM US LLP			Firm's EIN ▶ 42-0714325	
Firm's address ▶ 333 THORNALL ST., 6TH FLOOR EDISON, NJ 08837			Phone no. 732-515-7300	

VYNE THERAPEUTICS INC. (NOW YARROW BIOSCIENCE, INC.)
EIN: 45-3757789
Attachment to Form 8937

The information contained herein is provided pursuant to the requirements of Section 6045B of the Internal Revenue Code of 1986, as amended (the “Code”). This attachment includes a general summary of certain U.S. federal income tax laws and regulations relevant to the Reverse Stock Split (as defined below) and the tax basis of Vyne Therapeutics, Inc. (the “Company”) common stock, for a beneficial owner of Company common stock (each a “Stockholder”). This attachment does not constitute tax advice and does not purport to be complete or to describe the consequences that may apply to particular categories of Stockholders. The Issuer does not provide tax advice to its Stockholders, and any example provided below is merely illustrative. Stockholders are urged to consult their own tax advisors regarding the particular consequences to them of the Reverse Stock Split, including the applicability and the effect of all U.S. federal, state, local, and foreign tax laws.

Line 12 – VYNE prior to the merger; YARW following the merger/name change

Line 14

PLEASE NOTE THIS FORM RELATES SOLEY TO THE CASH DISTRIBUTIONS TO VYNE THERAPEUTICS, INC. SHAREHOLDERS OF RECORD AS OF JULY 22, 2026. PLEASE REFER TO THE OTHER FILINGS ON THIS SITE TO DETERMINE: THE EFFECT OF: (1) THE 1-50 REVERSE STOCK SPLIT FOR FORMER VYNE THERAPEUTICS, INC. SHAREHOLDERS AS WELL AS THE EFFECT OF THE (2) CONVERSIONS OF VYNE THERAPEUTICS SHARES INTO YARROW BIOSCIENCE, INC. SHARES;

a. A Special Dividend was declared by VYNE Therapeutics Inc.’s Board of Directors on July 10, 2026, in connection with the previously announced merger (the "Merger") with Yarrow Biosciences, Inc. (“Yarrow Biosciences”), pursuant to the Agreement and Plan of Merger and Reorganization, dated December 17, 2025.
b. The special cash dividend (the "Special Dividend") equals approximately $0.40242 per share of Vyne Therapeutics, Inc. (now Yarrow Bioscience, Inc.) (the "Company" or "VYNE") common stock payable on July 23, 2026, to all of Vyne's stockholders of record as of July 22, 2026. The estimated per share dividend is based on 42,989,506 shares of VYNE common stock and common stock equivalents outstanding as of July 22, 2026.
c. The cash distribution was not affected by the subsequent 1 for 50 reverse stock split.
d. Because the Special Dividend exceeds 25% of Vyne's stock price on the declaration date, it is subject to an ex-dividend date of one business day after the payment date pursuant to the rules of The Nasdaq Stock Market LLC ("Nasdaq"). Accordingly, Nasdaq has set July 24, 2026 as the ex-dividend date for the Special Dividend.

Line 15

a. The distribution of the Special Dividend of approximately $0.40242 per share should be treated first as a dividend to the extent of Vyne's current and accumulated earnings and profits, of which there are none as of this filing and none are expected. Therefore, this Special Dividend would be a non-taxable return of capital to the extent of the U.S. holder's basis in its Vyne common stock, and then as capital gain from the sale or exchange of Vyne common stock with respect to any remaining amount of the Special Dividend in excess of the U.S. holder’s basis in the Vyne shares. Such capital gain will be long-term capital gain if the U.S. holder's holding period in the Vyne common stock exceeds one year at the time of the special cash dividend.
b. Vyne currently has an accumulated deficit and expects additional losses in the current period. Thus, Vyne expects most or all of the distribution of the Special Dividend to be treated as other than a dividend for U.S. federal income tax purposes.

Line 16

a. The basis for each share of common stock held by a stockholder would be reduced by the approximate $0.40242 per share Special Dividend.
b. To the extent the distribution exceeds the adjusted basis of such stock, such excess (as computed by each shareholder separately) shall be treated as gain from the sale or exchange of property.

Line 17

Sections 301(c) and 316.

Line 18

Shareholders should consult their tax advisor to determine the tax impact of this transaction with respect to their individual facts and circumstances.

Line 19

a. The distribution is reportable for a Stockholder's taxable year that includes the July 24, 2026 ex dividend date.

b. Information contained within this Form 8937 should not be interpreted as tax advice. Stockholders are encouraged to consult with their own tax advisors regarding specific tax consequences of the Special Dividend, based on their specific facts and circumstances.